FindTrial
Sign In

To measure the serum cox 2 level ( inflammatory mediator) in healthy individuals and melasma patients and correlate with the severity of the disease

Comparison of serum COX 2 (cycloxygenase 2) levels in melasma patients and healthy controls and its correlation with disease severity . - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067537
Enrollment
82
Registered
2024-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: NIL: NIL

Sponsors

Dr surya Bramara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 18 years and above , patients of all gender , diagnosed with melasma clinically - MASI score indicating severity

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
To evaluate the disease severity in patients with melasma using MASI and Dermoscopy. To correlate the levels of serum Cox-2 with the disease severity of melasma.Timepoint: 18 months—

Primary

MeasureTime frame
1.to estimate the levels of COX2 serum levels in melasma patients 2.To compare cox-2 levels in the serum in melasma patients and healthy controls Timepoint: 18 months—

Countries

India

Contacts

Public ContactSurya Bramara

father muller medical college and research instittute

dr_martisj@fathermuller.in9845148112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026